EP0503022A1 - METHOD FOR DETECTION OF THE $g(b)-AMYLOID PROTEIN USING UNSPECIFIC BINDING OF OLIGONUCLEOTIDES - Google Patents

METHOD FOR DETECTION OF THE $g(b)-AMYLOID PROTEIN USING UNSPECIFIC BINDING OF OLIGONUCLEOTIDES

Info

Publication number
EP0503022A1
EP0503022A1 EP19910916158 EP91916158A EP0503022A1 EP 0503022 A1 EP0503022 A1 EP 0503022A1 EP 19910916158 EP19910916158 EP 19910916158 EP 91916158 A EP91916158 A EP 91916158A EP 0503022 A1 EP0503022 A1 EP 0503022A1
Authority
EP
European Patent Office
Prior art keywords
amyloid
oligonucleotides
amyloid protein
precursor
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910916158
Other languages
German (de)
French (fr)
Inventor
Stina SYRJÄNEN
Kari SYRJÄNEN
Outi Heinonen
Paavo Riekkinen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Locus Genex Oy
Original Assignee
Locus Genex Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Locus Genex Oy filed Critical Locus Genex Oy
Publication of EP0503022A1 publication Critical patent/EP0503022A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Definitions

  • the invention relates to the detection of proteins by means of oligonucleotides.
  • the invention may be utilized especially in diagnostics.
  • Alzheimer's disease is a disease resulting in a difficult dementia, in which the risk of falling ill increases along with aging. Symptoms of Alzheimer's disease are the progressive deterioration of memory, perception and other higher brain functions, which finally results in the patient's complete feeblemindedness.
  • the pathological changes caused by it are fairly well-known.
  • the most typical changes are the extracellular accumulation of amyloid protein on the walls of the cerebral membranes and blood vessels as well as as senile plaques.
  • the cyto-skelenton components of neurons aggregate intracellularly as so-called neurofi- brillary tangles.
  • the filamentary proteins may completely change the structure of the neuron, which finally results in the dystrophy and cell death of the neurons.
  • the number of amyloid plaques correlates fairly well with the deterioration of cognitive functions, the neuron loss and the decrease in neurotransmitters (Tanzi et al. 1989) .
  • Senile or neuritic plaques consist of an amyloid core, which is surrounded by a periphery comprised of dystrophic neurites and extracellular material.
  • the plaques may be dense, so-called classic plaques or diffuse concentrations formed of loosely interconnected material. Diffuse plaques have in fact been assumed to be pre-stages of denser formations, which may form during several years without first causing neurologic symptons (Joachim et al. 1989, Tanzi 1989) .
  • amyloid in the senile plaques forms of 6-10 nm stranded ⁇ -amyloid protein, whose identical subunits are arranged antiparallelly into a beta-structure.
  • This hydrofobic protein of ca. 4.2-4.5 kDa is synthesized most likely in neurons as part of a longer ⁇ -amyloid precursor protein.
  • the gene coding for the precursor protein is localized in the chromosome 21 (Goldgaber et al. 1978, Tanzi 1987) .
  • the ⁇ -amyloid precursor is a receptor-like, transmembranal glycosylated protein, in which two thirds are located in the extracellular state (Kang et al. 1987) .
  • the ⁇ -amyloid dipeptide is in turn located partly in the transmembranal area so that its proteolytic release from the precursor occurs either before the precursor*s loosening onto or after loosening from cellular membrane (Tanzi 1989) .
  • ⁇ -amyloid gene codes for at least three transcripts acting as models for polypeptides with 695, 751 and 770 amino acids.
  • the two longer polypep- tides contain an extra sequence with 56 the amino acid, which is 50% homogenous with the enzymes belonging to the so-called Kuniz's serine protease inhibitor family.
  • protease inhibitor sequence in the aggregation of the ⁇ -amyloid Two contradictory hypotheses corcerning the possible share of the protease inhibitor sequence in the aggregation of the ⁇ -amyloid have been presented: 1) it may prevent the cumulation of amyloid by inhibiting proteases which release ⁇ -peptide from the precursor, or 2 ) the protease inhibitor may advance the cumulation of amyloid by preventing specific proteinases from purifying the tissue from ⁇ -amyloid.
  • the function of the protease inhibitor sequence of the ⁇ -amyloid precursor protein and also its release from the precursor into an active enzyme are thus not known for certain.
  • the invention is based on the surprising discovery that oligonucleotides bind to the ⁇ -amyloid protein or its precursor.
  • the ⁇ -amyloid protein or its precursor thus binds DNA.
  • the binding occurs especially in the ⁇ -amyloid protein or its precursor present in a peripheral tissue (e.g. skin, mucous membrane) .
  • the phenomenon may be utilized especially in diagnostic tests (e.g. Alzheimer's disease, Down's syndrome, dementias, old persons).
  • the object of our examination was the expression of ⁇ - a yloid on the frontal cortex and hippocampus of Alzheimer patients.
  • the RNA in situ hybridization and as a specific tester was a cocktail formed by three short oligonucleotides corresponding to different areas of the ⁇ -amyloid sequence.
  • the oligonuc ⁇ leotides were labelled at the 3'-end with biotin.
  • antisense-RNA-oligonucleotides were synthesized complementary sense-RNA-oligonucleotides, which were labelled in the same way as the antisense probes.
  • the in situ hybridization was performed by using the routine methods of our laboratory (a hybridized biotinylated intron is allowed to bind to a streptavidine-alkaline phosphatase complex, which is in turn detected by means of a substrate reaction) .
  • the brain samples of 3 different Alzheimer patients as well as two normal samples were examined. As a result could be observed strong signals in the area of the cortex and hippocampus corresponding both by their location and shape to senile plaques.
  • a positive colouring was seen in the walls of blood vessels, as described in connection with the ⁇ -amyloid protein.
  • the sense probe we could to our surprise see the same result as when using the antisense probe.
  • the in situ hybridization was repeated several times to preclude a possible false positive reaction caused by endogenic biotin or alkaline phosphatase.
  • the in situ hybridization was repeated by using a radioactive label or other enzymes for the detection of a biotinylized hybrid (e.g. peroxidase) .
  • a biotinylized hybrid e.g. peroxidase
  • the results were always the same.
  • other oligonucleotides were tested, which deviated from the published sequence of ⁇ -amyloid (e.g. erb cancer gene or 18 and 16 of human papilloma virus (HPV) .
  • HPV human papilloma virus
  • the location of senile plaques and amyloid was additional ⁇ ly ensured by using conventional stainings: kongo, Bielschowski.
  • the samples were additionally stained also immunohistochemically by using as a primary antibody an antibody made against a commercial ⁇ -amyloid protein. These stainings gave considerably weaker signals, but the positive areas were the same.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention se rapporte à un procédé de détection de la protéine beta-amyloïde à partir d'un échantillon, au moyen de la réaction dudit échantillon avec un oligonucléotide. Ce procédé s'adresse particulièrement à la détection d'une amyloIdose apparentée, par exemple, à la maladie d'Alzheimer.The invention relates to a method for detecting beta-amyloid protein from a sample, by means of the reaction of said sample with an oligonucleotide. This method is particularly intended for the detection of an amyloidosis related, for example, to Alzheimer's disease.

Description

Method for detection of the β-amyloid protein using unspecific binding of oligonucleotides
Technical field
The invention relates to the detection of proteins by means of oligonucleotides. The invention may be utilized especially in diagnostics.
Background
Alzheimer's disease is a disease resulting in a difficult dementia, in which the risk of falling ill increases along with aging. Symptoms of Alzheimer's disease are the progressive deterioration of memory, perception and other higher brain functions, which finally results in the patient's complete feeblemindedness.
Although the reasons for the outbreak of Alzheimer's disease are not known, the pathological changes caused by it are fairly well-known. The most typical changes are the extracellular accumulation of amyloid protein on the walls of the cerebral membranes and blood vessels as well as as senile plaques. In addition, the cyto-skelenton components of neurons aggregate intracellularly as so-called neurofi- brillary tangles. In both cases, the filamentary proteins may completely change the structure of the neuron, which finally results in the dystrophy and cell death of the neurons. The number of amyloid plaques correlates fairly well with the deterioration of cognitive functions, the neuron loss and the decrease in neurotransmitters (Tanzi et al. 1989) .
Senile or neuritic plaques consist of an amyloid core, which is surrounded by a periphery comprised of dystrophic neurites and extracellular material. The plaques may be dense, so-called classic plaques or diffuse concentrations formed of loosely interconnected material. Diffuse plaques have in fact been assumed to be pre-stages of denser formations, which may form during several years without first causing neurologic symptons (Joachim et al. 1989, Tanzi 1989) .
The amyloid in the senile plaques forms of 6-10 nm stranded β-amyloid protein, whose identical subunits are arranged antiparallelly into a beta-structure. This hydrofobic protein of ca. 4.2-4.5 kDa is synthesized most likely in neurons as part of a longer β-amyloid precursor protein. The gene coding for the precursor protein is localized in the chromosome 21 (Goldgaber et al. 1978, Tanzi 1987) .
One reason for the cumulation of amyloid has been assumed to be a defect in the gene locus, since a corresponding plaque formation also occurs on nearly all Down's syndrome patients of over 40 years (trisomy in chromosome 21) , whereby the overproduction of amyloid can be explained by means of an extra gene. An autosomally dominant gene defect in the chromosome 21 has been observed in patients with the hereditary Alzheimer's disease, but it has not been possible to prove a connection between it and the β- amyloid gene located in the same chromosome (St. George- Hyslop et al. 1978, Tanzi et al. 1987).
The β-amyloid precursor is a receptor-like, transmembranal glycosylated protein, in which two thirds are located in the extracellular state (Kang et al. 1987) . The β-amyloid dipeptide is in turn located partly in the transmembranal area so that its proteolytic release from the precursor occurs either before the precursor*s loosening onto or after loosening from cellular membrane (Tanzi 1989) .
It has been observed that the β-amyloid gene codes for at least three transcripts acting as models for polypeptides with 695, 751 and 770 amino acids. The two longer polypep- tides contain an extra sequence with 56 the amino acid, which is 50% homogenous with the enzymes belonging to the so-called Kuniz's serine protease inhibitor family. Two contradictory hypotheses corcerning the possible share of the protease inhibitor sequence in the aggregation of the β-amyloid have been presented: 1) it may prevent the cumulation of amyloid by inhibiting proteases which release β-peptide from the precursor, or 2 ) the protease inhibitor may advance the cumulation of amyloid by preventing specific proteinases from purifying the tissue from β-amyloid. The function of the protease inhibitor sequence of the β-amyloid precursor protein and also its release from the precursor into an active enzyme are thus not known for certain.
General description of invention
The invention and certain preferred applications thereof are defined in the patent claims.
The invention is based on the surprising discovery that oligonucleotides bind to the β-amyloid protein or its precursor. The β-amyloid protein or its precursor thus binds DNA. The binding occurs especially in the β-amyloid protein or its precursor present in a peripheral tissue (e.g. skin, mucous membrane) . The phenomenon may be utilized especially in diagnostic tests (e.g. Alzheimer's disease, Down's syndrome, dementias, old persons).
Detailed description of invention
The object of our examination was the expression of β- a yloid on the frontal cortex and hippocampus of Alzheimer patients. As a research method was used the RNA in situ hybridization and as a specific tester was a cocktail formed by three short oligonucleotides corresponding to different areas of the β-amyloid sequence. The oligonuc¬ leotides were labelled at the 3'-end with biotin. For specific antisense-RNA-oligonucleotides were synthesized complementary sense-RNA-oligonucleotides, which were labelled in the same way as the antisense probes. The in situ hybridization was performed by using the routine methods of our laboratory (a hybridized biotinylated intron is allowed to bind to a streptavidine-alkaline phosphatase complex, which is in turn detected by means of a substrate reaction) . The brain samples of 3 different Alzheimer patients as well as two normal samples were examined. As a result could be observed strong signals in the area of the cortex and hippocampus corresponding both by their location and shape to senile plaques. In additi- on, a positive colouring was seen in the walls of blood vessels, as described in connection with the β-amyloid protein. When we used the sense probe, we could to our surprise see the same result as when using the antisense probe. (When a specific mRNA expression is examined, the sense probe should produce a negative result.) A negative result was by contrast obtained, when water was used instead of the gene probe; the reactions were otherwise performed in the same way as when using the sense/antisen¬ se probe. All colouring results were negative, when the normal samples were subjected to examination.
The in situ hybridization was repeated several times to preclude a possible false positive reaction caused by endogenic biotin or alkaline phosphatase.
Furthermore, the in situ hybridization was repeated by using a radioactive label or other enzymes for the detection of a biotinylized hybrid (e.g. peroxidase) . However, the results were always the same. Owing to the results, also other oligonucleotides were tested, which deviated from the published sequence of β-amyloid (e.g. erb cancer gene or 18 and 16 of human papilloma virus (HPV) . The results remained the same.
The location of senile plaques and amyloid was additional¬ ly ensured by using conventional stainings: kongo, Bielschowski. The samples were additionally stained also immunohistochemically by using as a primary antibody an antibody made against a commercial β-amyloid protein. These stainings gave considerably weaker signals, but the positive areas were the same.
Our results indicated that oligonucleotides (independently of the sequence) bind to the β-amyloid protein or its precursor.
It has previously been postulated (Pepys and Butler, 1987 Breathnach et al. 1989) that serum's amyloid P binds DNA. This binding is dependent on calcium. It has generally been believed that serum's P amyloid cannot be seen in the amyloid cumulations in connection with Alzheimer's disease. However, it has recently been shown that serum P's antibodies could provide reactivity also in the brain area (Kalaria and Grahovac, 1990) .
Joachim et al., 1989, indicated that β-amyloid is also found in the skin samples of Alzheimer patients (the method used was immunohistology) . We have been able to show that oligonucleotides bind to β-amyloid or its precursor also in the skin sample of an Alzheimer patient.
Our results show that the cumulation in amyloid is a secondary phenomenon and not only related to the brain area.

Claims

Claims
1. A method for detecting the β-amyloid protein or its precursor from a sample, characterized in that the sample is reacted with an oligonucleotide.
2. A method according to Claim 1 to be used in a diagnos¬ tic test.
3. A method according to Claim 2 for detecting an amy- loidosis.
4. A method according to Claim 3 for detecting an amy- loidosis from a peripheral tissue sample, such as from a skin or mucous-membrane sample.
5. An oligonucleotide probe, characterized in that it is intended to be used for detecting the β-amyloid protein or its precursor from a sample.
EP19910916158 1990-09-27 1991-09-27 METHOD FOR DETECTION OF THE $g(b)-AMYLOID PROTEIN USING UNSPECIFIC BINDING OF OLIGONUCLEOTIDES Withdrawn EP0503022A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI904766A FI904766A (en) 1990-09-27 1990-09-27 FOERFARANDE FOER DETEKTERING AV PROTEIN.
FI904766 1990-09-27

Publications (1)

Publication Number Publication Date
EP0503022A1 true EP0503022A1 (en) 1992-09-16

Family

ID=8531126

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910916158 Withdrawn EP0503022A1 (en) 1990-09-27 1991-09-27 METHOD FOR DETECTION OF THE $g(b)-AMYLOID PROTEIN USING UNSPECIFIC BINDING OF OLIGONUCLEOTIDES

Country Status (5)

Country Link
EP (1) EP0503022A1 (en)
JP (1) JPH05502512A (en)
CA (1) CA2069731A1 (en)
FI (1) FI904766A (en)
WO (1) WO1992006376A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ242955A (en) * 1991-06-13 1995-01-27 Ici Plc Dna containing gene sequences corresponding to sequences causing alzheimers disease, detection, recombinant yeast with such code

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274826B1 (en) * 1986-11-17 1998-08-12 Scios Inc. Recombinant Alzheimer's amyloid protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9206376A1 *

Also Published As

Publication number Publication date
JPH05502512A (en) 1993-04-28
WO1992006376A1 (en) 1992-04-16
CA2069731A1 (en) 1992-03-28
FI904766A0 (en) 1990-09-27
FI904766A (en) 1992-03-28

Similar Documents

Publication Publication Date Title
EP2354795B1 (en) Methods and compositions relating to Alzheimer`s disease
US5270165A (en) Method of diagnosis of amyloidoses
EP1476758B1 (en) Detection and/or monitoring of synuclein-related diseases
US20060134108A1 (en) Method for retarding or precluding Alzheimer's dementia
Mann et al. An analysis of the morphology of senile plaques in Down's syndrome patients of different ages using immunocytochemical and lectin histochemical techniques
Vinters et al. Immunohistochemical study of cerebral amyloid angiopathy. III. Widespread Alzheimer A4 peptide in cerebral microvessel walls colocalizes with gamma trace in patients with leukoencephalopathy
EP0540591B1 (en) Cell necrosis detection through assays for spectrin and breakdown products thereof
WO1992000374A1 (en) Protease clipsin and method of use
JPH09507748A (en) Isolated composition of high-density microspheres derived from mammalian brain tissue and antibodies thereto
JP2005510575A (en) IG heavy chain, IG kappa, and IG lambda biopolymer markers that predict Alzheimer's disease
EP0503022A1 (en) METHOD FOR DETECTION OF THE $g(b)-AMYLOID PROTEIN USING UNSPECIFIC BINDING OF OLIGONUCLEOTIDES
Navarro et al. Immunohistochemical presence of apolipoprotein D in senile plaques
JP2005523422A (en) Protein biopolymer markers that predict insulin resistance
JP2005510728A (en) Protein biopolymer markers that predict insulin resistance
JP2005523420A (en) Complement C3 precursor biopolymer marker indicating Alzheimer's disease
Ishiguro et al. Differential expression of α 1-antichymotrypsin in the aged human brain
JP2005523419A (en) Fibronectin and fibrinogen biopolymer markers exhibiting insulin resistance
US20030017492A1 (en) Methods for diagnosis and treatment of chronic immune diseases
JP2005510727A (en) HP and apolipoprotein biopolymer markers to predict Alzheimer's disease
KR20140000977A (en) Marker for diagnosing diabetic retinopathy and use thereof
JP2005523425A (en) Apolipoprotein biopolymer marker predicting Alzheimer's disease
AU2011253636B2 (en) Methods and compositions relating to alzheimer's disease
JP2005510726A (en) Glycoprotein and apolipoprotein biopolymer markers to predict Alzheimer's disease
Navarro et al. Apolipoprotein D in Senile Plaques
US20030077674A1 (en) Methods for diagnosis and treatment of chronic immune diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920523

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19940908

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950119